Merck (MRK) Cost of Revenue (2009 - 2026)

Merck (MRK) has reported Cost of Revenue for 18 consecutive years, with $4.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 23.56% year-over-year to $4.4 billion in Q2 2026; TTM through Jun 2026 was $18.0 billion, a 20.91% increase from a year earlier, with the FY2025 full-year figure at $16.4 billion, up 7.83% from the prior year.
• Cost of Revenue was $4.4 billion for Q2 2026 at Merck, up from $4.2 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $5.6 billion in Q4 2025 and troughed at $3.4 billion in Q1 2025.
• A 5-year average of $4.1 billion and a median of $3.9 billion in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue soared 68.18% in 2022 and slipped 27.03% in 2023, its largest moves.
• Over 5 years, Cost of Revenue stood at $3.9 billion in 2022, then climbed by 0.8% to $3.9 billion in 2023, then declined by 2.15% to $3.8 billion in 2024, then surged by 45.01% to $5.6 billion in 2025, then decreased by 20.83% to $4.4 billion in 2026.
• The last three Cost of Revenue figures came in at $4.4 billion (Q2 2026), $4.2 billion (Q1 2026), and $5.6 billion (Q4 2025), per Business Quant data.